A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 21 Dec 2018 Planned End Date changed from 1 Oct 2020 to 11 May 2020.
- 21 Dec 2018 Planned primary completion date changed from 31 Mar 2020 to 25 Nov 2019.
- 31 Aug 2018 Biomarkers information updated